Impact of follow ups, time interval and study duration in diffusion & myelin MRI clinical study in MS.

Diffusion MRI Follow-ups Healthy controls Inhomogeneous magnetization transfer Longitudinal study Multiple Sclerosis Study duration Time-interval

Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2023
Historique:
received: 12 06 2023
revised: 04 10 2023
accepted: 10 10 2023
pubmed: 20 10 2023
medline: 20 10 2023
entrez: 19 10 2023
Statut: ppublish

Résumé

It is currently unknown how quantitative diffusion and myelin MRI designs affect the results of a longitudinal study. We used two independent datasets containing 6 monthly MRI measurements from 20 healthy controls and 20 relapsing-remitting multiple sclerosis (RR-MS) patients. Six designs were tested, including 3 MRI acquisitions, either over 6 months or over a shorter study duration, with balanced (same interval) or unbalanced (different interval) time intervals between MRI acquisitions. First, we show that in RR-MS patients, the brain changes over time obtained with 3 MRI acquisitions were similar to those observed with 5 MRI acquisitions and that designs with an unbalanced time interval showed the highest similarity, regardless of study duration. No significant brain changes were found in the healthy controls over the same periods. Second, the study duration affects the sample size in the RR-MS dataset; a longer study requires more subjects and vice versa. Third, the number of follow-up acquisitions and study duration affect the sensitivity and specificity of the associations with clinical parameters, and these depend on the white matter bundle and MRI measure considered. Together, this suggests that the optimal design depends on the assumption of the dynamics of change in the target population and the accuracy required to capture these dynamics. Thus, this work provides a better understanding of key factors to consider in a longitudinal study and provides clues for better strategies in clinical trial design.

Identifiants

pubmed: 37857232
pii: S2213-1582(23)00220-6
doi: 10.1016/j.nicl.2023.103529
pmc: PMC10591008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103529

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Manon Edde (M)

Imeka Solutions, Inc., Sherbrooke, QC, Canada; Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: eddemanon@gmail.com.

Francis Houde (F)

Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Guillaume Theaud (G)

Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Matthieu Dumont (M)

Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Guillaume Gilbert (G)

MR Clinical Science, Philips Healthcare Canada, Mississauga, Ontario, Canada.

Jean-Christophe Houde (JC)

Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Loïka Maltais (L)

Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Antoine Théberge (A)

Université de Sherbrooke, Sherbrooke, QC, Canada; Videos & Images Theory and Analytics Laboratory (VITAL), Université de Sherbrooke, Sherbrooke, QC, Canada.

Moussa Doumbia (M)

Université de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.

Ann-Marie Beaudoin (AM)

Université de Sherbrooke, Sherbrooke, QC, Canada; Université de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.

Emmanuelle Lapointe (E)

Université de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.

Muhamed Barakovic (M)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel Switzerland, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Stefano Magon (S)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel Switzerland, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Maxime Descoteaux (M)

Imeka Solutions, Inc., Sherbrooke, QC, Canada; Université de Sherbrooke, Sherbrooke, QC, Canada.

Classifications MeSH